The median progression-free survival was @ months with continuous lenalidomide-dexamethasone , @ months with @ cycles of lenalidomide-dexamethasone , and @ months with MPT ( hazard ratio for the risk of progression or death , @ for continuous lenalidomide-dexamethasone vs. MPT and @ for continuous lenalidomide-dexamethasone vs. @ cycles of lenalidomide-dexamethasone ; P < @ for both comparisons ) .